TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25435541

Group type: EXPERIMENTAL
Intervention: Population screening (PS) arm
Number of subjects: 1017

Group type: COMPARATOR
Intervention: Family history (FH) arm
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: Both PS and FH arms
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: Population-based genetic testing
Number of subjects: 1017
Study: 22960949

Group type: EXPERIMENTAL
Intervention: Radial optic neurotomy (RON)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (IVT)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 21990403

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 6186

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 6186

Group type: COMPARATOR
Intervention: Age ≥ 70 years
Number of subjects: 6186

Group type: COMPARATOR
Intervention: Comorbidity score
Number of subjects: 6186
Study: 19307225

Group type: EXPERIMENTAL
Intervention: Antireflux treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical scoring system
Number of subjects: 0
Study: 16352871

Group type: EXPERIMENTAL
Intervention: on-line haemodiafiltration (oHDF)
Number of subjects: 70

Group type: COMPARATOR
Intervention: haemodialysis (HD)
Number of subjects: 70
Study: 15138682

Group type: EXPERIMENTAL
Intervention: Explanatory Model Interview (EMIC)
Number of subjects: 87
Study: 11294367

Group type: EXPERIMENTAL
Intervention: Salmeterol 100 microg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Salmeterol 100 microg/fluticasone propionate 500 microg
Number of subjects: 28
Study: 9148578

Group type: EXPERIMENTAL
Intervention: Autogenic training (AT) applied to 70 patients
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (without AT) consisting of 45 patients
Number of subjects: 115
Study: 8458448

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA) depot (Enantone Depot, Takeda, Italy) administered preoperatively
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group (no LA depot)
Number of subjects: 193
Study: 2429085

Group type: EXPERIMENTAL
Intervention: Methyldopa (500‐1000 mg daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30565854

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg day−1 for 4 weeks
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 245
Study: 30442608

Group type: EXPERIMENTAL
Intervention: 3D Relative Joint Displacement (3DRJDP) and 6D Symmetric Relative Joint Displacement (6DSymRJDP) features
Number of subjects: 45

Group type: COMPARATOR
Intervention: Existing features focusing on individual joints
Number of subjects: 45
Study: 24714541

Group type: EXPERIMENTAL
Intervention: HMB-FA (3 g) and ATP (400 mg) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24706266

Group type: EXPERIMENTAL
Intervention: Synbiotic bread (1 × 10(8) CFU Lactobacillus sporogenes and 0.07 g inulin per 1 g)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Probiotic bread (1 × 10(8) CFU Lactobacillus sporogenes per 1 g)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control bread
Number of subjects: 78
Study: 21450196

Group type: EXPERIMENTAL
Intervention: Mental practice intervention embedded in regular therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard therapy as usual (control group)
Number of subjects: 36
Study: 20450590

Group type: EXPERIMENTAL
Intervention: Calcium-Magnesium infusion
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Glutathione (GSH)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Chemotherapy alone (normal saline)
Number of subjects: 93
Study: 17364394

Group type: EXPERIMENTAL
Intervention: DAART (Directly Administered Antiretroviral Therapy)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: DAART
Number of subjects: 250
Study: 15721975

Group type: EXPERIMENTAL
Intervention: Feedback group (physician feedback on physical activity level)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Advice plus group (further advice, stage matched leaflets, and a 45-min counselling session)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Both groups (feedback and advice plus)
Number of subjects: 90
Study: 14500163

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 10325288

Group type: EXPERIMENTAL
Intervention: Resection/ablation of visible endometriosis (54 patients)
Number of subjects: 101

Group type: COMPARATOR
Intervention: No treatment (diagnostic laparoscopy only, 47 patients)
Number of subjects: 101
Study: 8961453

Group type: EXPERIMENTAL
Intervention: Pain facility treatment
Number of subjects: 236
Study: 1763680

Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no immuno-suppressive treatment)
Number of subjects: 0
Study: 6955993

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3902906

Group type: EXPERIMENTAL
Intervention: Listerine antiseptic (LA)
Number of subjects: 78
Study: 29530858

Group type: EXPERIMENTAL
Intervention: Iclaprim (80 mg) administered intravenously every 12 h for 5 to 14 days
Number of subjects: 613

Group type: COMPARATOR
Intervention: Vancomycin (15 mg/kg of body weight) administered intravenously every 12 h for 5 to 14 days
Number of subjects: 613
Study: 26560249

Group type: EXPERIMENTAL
Intervention: Pulmonary artery pressure guided management (treatment group)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Open access to pulmonary artery pressure information for former control group
Number of subjects: 550
Study: 25045258

Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg
Number of subjects: 1838

Group type: EXPERIMENTAL
Intervention: Olodaterol 10 μg
Number of subjects: 1838

Group type: EXPERIMENTAL
Intervention: Formoterol 12 μg
Number of subjects: 1838

Group type: EXPERIMENTAL
Intervention: Olodaterol
Number of subjects: 1838

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1838
Study: 22116265

Group type: EXPERIMENTAL
Intervention: Posterior cruciate ligament-retaining prostheses
Number of subjects: 60

Group type: COMPARATOR
Intervention: Posterior cruciate ligament-sacrificing prostheses
Number of subjects: 60
Study: 20546269

Group type: EXPERIMENTAL
Intervention: Euglycaemia (5.0 mmol/l)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Hyperglycaemia (11.0 mmol/l)
Number of subjects: 7
Study: 19034035

Group type: EXPERIMENTAL
Intervention: Clopidogrel 37.5 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 15907330

Group type: EXPERIMENTAL
Intervention: Heel pads of diabetic subjects
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heel pads of nondiabetic subjects
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anatomically realistic heel-pad model
Number of subjects: 40
Study: 11394468

Group type: EXPERIMENTAL
Intervention: ECU muscle pain
Number of subjects: 12

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 12
Study: 9507380

Group type: EXPERIMENTAL
Intervention: Leukapheresis initiated based on CD34+ blood level exceeding 20,000 CD34+/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leukapheresis for high-level mobilizers (> 80,000 CD34+ cells/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leukapheresis for low-level mobilizers (< 40,000 CD34+ cells/ml)
Number of subjects: 0
Study: 8064949

Group type: EXPERIMENTAL
Intervention: Maloprim (pyrimethamine 12.5 mg + dapsone 100 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 3376912

Group type: EXPERIMENTAL
Intervention: Low-fat, carbohydrate-rich diet (total fat 22 en%) for 36 days
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: High-fat, olive-oil-rich diet (oleic acid 24 en%, total fat 41 en%) for 36 days
Number of subjects: 47

Group type: COMPARATOR
Intervention: Comparison between low-fat and high-fat diets
Number of subjects: 47
Study: 30183875

Group type: EXPERIMENTAL
Intervention: Ear acupuncture (Treatment)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control
Number of subjects: 110
Study: 26659915

Group type: EXPERIMENTAL
Intervention: Obinutuzumab 1600/800 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obinutuzumab 400/400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Obinutuzumab 1000 mg fixed-dose regimen
Number of subjects: 0
Study: 25042488

Group type: EXPERIMENTAL
Intervention: Chondroprotector АРТРА with melaxen (melatonin 3 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Chondroprotector АРТРА with melaxen (melatonin)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Chondroprotector АРТРА and diclofenac
Number of subjects: 120
Study: 22119856

Group type: EXPERIMENTAL
Intervention: Peripheral venous access for CS cannulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Central venous access for CS cannulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoroscopy time for CS cannulation
Number of subjects: 0
Study: 20647201

Group type: EXPERIMENTAL
Intervention: Early treatment with zidovudine, lamivudine, and efavirenz therapy within 2 weeks after enrollment
Number of subjects: 816

Group type: COMPARATOR
Intervention: Standard treatment starting when CD4+ T-cell count fell to 200 or less or when clinical AIDS developed
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Early treatment with zidovudine, lamivudine, and efavirenz therapy
Number of subjects: 816
Study: 18571088

Group type: EXPERIMENTAL
Intervention: Viscodissection (Group 2)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hydrodissection (Group 1)
Number of subjects: 14
Study: 16003229

Group type: EXPERIMENTAL
Intervention: Early corticosteroid withdrawal (CSWD)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Chronic corticosteroid therapy (CCST)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Corticosteroid rejection therapy in CSWD patients
Number of subjects: 301
Study: 11809343

Group type: EXPERIMENTAL
Intervention: HRT 1 (1 mg 17beta‐estradiol daily + 0.025 mg gestodene cyclically every month)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: HRT 2 (1 mg 17beta‐estradiol daily + 0.025 mg gestodene cyclically every third month)
Number of subjects: 321

Group type: COMPARATOR
Intervention: No HRT (control group)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: HRT (both HRT 1 and HRT 2)
Number of subjects: 321
Study: 10357496

Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT) with didanosine (ddI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT) with zalcitabine (ddC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zidovudine (AZT) alone
Number of subjects: 0
Study: 7587243

Group type: EXPERIMENTAL
Intervention: Monitoring devices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternatives to randomized, controlled trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommendations for device testing
Number of subjects: 0
Study: 2225706

Group type: EXPERIMENTAL
Intervention: Cloprednol
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (Beclomethasone)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Prednisone (Postmenopausal women)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cloprednol (Postmenopausal women)
Number of subjects: 39
Study: 848577

Group type: EXPERIMENTAL
Intervention: Chlorpromazine with imipramine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Thiothixene with placebo
Number of subjects: 55
Study: 30357395

Group type: EXPERIMENTAL
Intervention: Intensive SBP management (<120 mm Hg)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Standard SBP management (<140 mm Hg)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control participants (no incident CKD)
Number of subjects: 162
Study: 26700126

Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Number of subjects: 537

Group type: COMPARATOR
Intervention: Doxorubicin-only
Number of subjects: 537
Study: 25195125

Group type: EXPERIMENTAL
Intervention: Atorvastatin only
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ivabradine only
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ivabradine and atorvastatin
Number of subjects: 200

Group type: COMPARATOR
Intervention: No study drugs
Number of subjects: 200
Study: 22227183

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D (1,25(OH)₂D)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: eGFR
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D (1,25(OH)₂D), plasma Ca²⁺, daily physical activity
Number of subjects: 26
Study: 19632878

Group type: EXPERIMENTAL
Intervention: Strength training in lengthened position
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study: 17493295

Group type: EXPERIMENTAL
Intervention: Brief CBT (6-week)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Standard CBT (12-week)
Number of subjects: 72
Study: 15740939

Group type: EXPERIMENTAL
Intervention: Thymectomy through manubriotomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Thymectomy through median sternotomy
Number of subjects: 50
Study: 12045763

Group type: EXPERIMENTAL
Intervention: Bionator appliance
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: FR-2 appliance
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 66
Study: 10433584

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine
Number of subjects: 112

Group type: COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine
Number of subjects: 112
Study: 7731378

Group type: EXPERIMENTAL
Intervention: Climen (2 mg estradiol valerate and 1 mg cyproterone acetate)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Prempak-C (0.625 mg conjugated equine estrogens and 0.15 mg norgestrel)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Climen
Number of subjects: 38

Group type: COMPARATOR
Intervention: Prempak-C
Number of subjects: 38
Study: 1696662

Group type: EXPERIMENTAL
Intervention: verapamil 160 mg b.i.d.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: atenolol 50 mg b.i.d.
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 7438948

Group type: EXPERIMENTAL
Intervention: Urecholine
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Dibenzyline (10 mg doses orally, four and eight hours after surgery)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 263
Study: 30779128

Group type: EXPERIMENTAL
Intervention: Higher serum thioproline and thioproline combined with cystine and cysteine
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Dipeptide leucylglycine
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Three gamma‐glutamyl amino acids
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Ketone body 3‐hydroxybutyrate (BHBA), acyl carnitines, and dicarboxylic fatty acids
Number of subjects: 523
Study: 28243722

Group type: EXPERIMENTAL
Intervention: 12 × 0.5 Gy (experimental group)
Number of subjects: 127

Group type: COMPARATOR
Intervention: 6 × 1 Gy (standard group)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Re-irradiation with standard dose
Number of subjects: 127
Study: 25339642

Group type: COMPARATOR
Intervention: Leaflet and advice (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Joint protection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hand exercises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Joint protection plus hand exercises
Number of subjects: 0
Study: 24321380

Group type: EXPERIMENTAL
Intervention: Intermittent Positive Pressure Breathing (IPPB)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Temporary Positive Expiratory Pressure (TPEP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Pharmacological therapy alone (Control group)
Number of subjects: 45
Study: 21942813

Group type: EXPERIMENTAL
Intervention: Iron-rich bread (3-4 slices daily for 6 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control bread (3-4 slices daily for 6 weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (Iron-rich and Control)
Number of subjects: 33
Study: 19542983

Group type: EXPERIMENTAL
Intervention: Pregabalin 300-450 mg/day
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg/day
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (alprazolam or lorazepam)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1002
Study: 17479606

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide plus inhaled formoterol fumarate
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide and oral montelukast sodium therapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 67
Study: 15727375

Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone intra‐articular injection
Number of subjects: 26

Group type: COMPARATOR
Intervention: triamcinolone oral tablets
Number of subjects: 26
Study: 11756910

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Inhalational anesthesia (Control)
Number of subjects: 50
Study: 9691504

Group type: EXPERIMENTAL
Intervention: Nursing intervention designed to increase hope
Number of subjects: 96

Group type: COMPARATOR
Intervention: Attention control group participating in the 'Learning to Live with Cancer' program
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 1362568

Group type: EXPERIMENTAL
Intervention: Taxol administered as a 120 h infusion at 36 mg/m2/d
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Taxol administered as a 120 h infusion at 30 mg/m2/d
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Taxol administered as a 120 h infusion
Number of subjects: 20
Study: 3815713

Group type: EXPERIMENTAL
Intervention: WAT40
Number of subjects: 24

Group type: COMPARATOR
Intervention: RSS
Number of subjects: 24

Group type: COMPARATOR
Intervention: SAS40
Number of subjects: 24

Group type: COMPARATOR
Intervention: SAS40 vs RSS
Number of subjects: 24
Study: 30150328

Group type: EXPERIMENTAL
Intervention: REMOTE‐CR (telerehabilitation)
Number of subjects: 162

Group type: COMPARATOR
Intervention: CBexCR (centre-based rehabilitation)
Number of subjects: 162
Study: 29704940

Group type: EXPERIMENTAL
Intervention: Pergolide treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 48
Study: 27310494

Group type: EXPERIMENTAL
Intervention: Higher health literacy
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Caucasian participants (n = 63)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Adjusting for health literacy
Number of subjects: 198
Study: 24722044

Group type: EXPERIMENTAL
Intervention: Brief educational intervention (tailored written stroke information, verbal reinforcement of information for 3 months after discharge, and provision of a telephone number)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study: 23177103

Group type: EXPERIMENTAL
Intervention: Venous sac embolization (VSE)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Transcatheter feeding artery embolization (FAE)
Number of subjects: 21
Study: 20703160

Group type: EXPERIMENTAL
Intervention: Double-step strategy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single-step strategy
Number of subjects: 12
Study: 17931928

Group type: COMPARATOR
Intervention: Hand/rotary technique
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Hand/rotary/ultrasound technique
Number of subjects: 31
Study: 16028649

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment (0.25 mg/kg on days 1-7, 0.12 mg/kg on days 8-14, 0.05 mg/kg on days 15-21, 0.02 mg/kg on days 21-28)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (no dexamethasone treatment)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 116
Study: 11996616

Group type: EXPERIMENTAL
Intervention: Education every 2 weeks while in jail
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Incentive for visiting the tuberculosis clinic within 1 month of release
Number of subjects: 558

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Education group
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Incentive group
Number of subjects: 558

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Education group (among those who went to the tuberculosis clinic)
Number of subjects: 558
Study: 9788977

Group type: EXPERIMENTAL
Intervention: Human parathyroid hormone 1-34 (hPTH 1-34)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estrogen-only group (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Markers of bone formation during the first 3 months of PTH treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Markers of bone resorption during the first 3 months of PTH treatment
Number of subjects: 0
Study: 7587796

Group type: EXPERIMENTAL
Intervention: Nicotine (12 mg chewing gum)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control period (no chewing gum)
Number of subjects: 11
Study: 2262701

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of metoclopramide and ranitidine
Number of subjects: 0
Study: 7377659

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg IV, repeated doses every six hours)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 95
Study: 31049835

Group type: EXPERIMENTAL
Intervention: High temperature treatment (30–40 °C) for 15 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (25 °C)
Number of subjects: 60